Infectious Diseases Department, Sterling Hospital, Ahmedabad 380052, India.
Infectious Diseases and Tropical Medicine Clinic, Gala Business Center II, Off C G Road, Ahmedabad 380006, India.
Indian J Med Microbiol. 2023 Jan-Feb;41:28-32. doi: 10.1016/j.ijmmb.2022.12.004. Epub 2022 Dec 27.
To understand the benefits of COVID-19 vaccination (Covishield, Covaxin) on clinical features and outcome of COVID-19 during the third wave in India.
The primary study aim was to describe the clinical profile and outcome of COVID-19 regarding their vaccination and to identify risk factors for disease progression in vaccinated patients. This was a prospective observational multicentric study of COVID-19 attended by Infectious Disease physicians during January 15, 2022 to February 15, 2022. Adult patients with positive RT-PCR or rapid antigen test for COVID-19 were enrolled. Patient received treatment as per local institutional protocol. Chi square test for categorical and Mann Whitney test for continuous variables were applied for the analysis. Logistic regression was used to calculate adjusted odds ratios.
A total of 788 patients were included in analysis out of 883 enrolled patients from 13 centers across Gujarat. By the end of two weeks' follow up, 22 patients (2.8%) had expired. The Median age of subjects was 54 years, with a (55.8%) male. 90% of the subjects were vaccinated, majority (77%) of them had received 2 doses of vaccine with Covishield (659, 93%). Mortality among the non-vaccinated was significantly (11.4%) higher than vaccinated (1.8%). Logistic regression analysis showed numbers of comorbidities (p = 0.027), baseline higher WBC count (p = 0.02), higher NLR (p = 0.016), and Ct value (p = 0.046) were associated with mortality while vaccination was associated with survival (p = 0.001). The factors associated with mortality among vaccinated were age, comorbidities, baseline higher WBC, NLR, and CRP.
Omicron variant was associated with mild symptoms. Clinical and laboratory risk factors for getting severe disease with Omicron variant were the same with previous SARS CoV-2 strain. Two doses of vaccine protect people against severe disease and death. Age, comorbidities, baseline leucocytosis, high NLR, elevated CRP are the risk factors for poor outcome in vaccinated patients.
了解 COVID-19 疫苗(Covishield、Covaxin)在印度第三波疫情期间对 COVID-19 临床特征和结局的影响。
本研究的主要目的是描述 COVID-19 的临床特征和结局,以及确定接种疫苗患者疾病进展的危险因素。这是一项在 2022 年 1 月 15 日至 2 月 15 日期间由传染病医生进行的 COVID-19 前瞻性观察性多中心研究。招募了 RT-PCR 或快速抗原检测阳性的成年 COVID-19 患者。患者接受了根据当地机构方案的治疗。采用卡方检验进行分类变量分析,采用曼-惠特尼检验进行连续变量分析。采用 logistic 回归计算调整后的优势比。
共纳入了 883 名患者,其中有 788 名患者符合分析条件,这些患者来自古吉拉特邦的 13 个中心。在两周的随访结束时,有 22 名患者(2.8%)死亡。患者的中位年龄为 54 岁,男性占 55.8%。90%的患者接种了疫苗,其中大多数(77%)接种了两剂 Covishield(659 人,93%)。未接种疫苗患者的死亡率(11.4%)明显高于接种疫苗患者(1.8%)。logistic 回归分析显示,合并症数量(p=0.027)、基线白细胞计数较高(p=0.02)、较高的 NLR(p=0.016)和 Ct 值(p=0.046)与死亡率相关,而接种疫苗与生存率相关(p=0.001)。在接种疫苗的患者中,与死亡率相关的因素是年龄、合并症、基线白细胞计数、NLR 和 CRP。
Omicron 变异株与轻症相关。Omicron 变异株引起严重疾病的临床和实验室危险因素与以前的 SARS CoV-2 株相同。两剂疫苗可预防严重疾病和死亡。年龄、合并症、基线白细胞增多、高 NLR、升高的 CRP 是接种疫苗患者不良结局的危险因素。